Nicorol is applied in situations involving certain distressing symptoms of chronic stable angina pectoris, a chronic heart condition characterized by symptoms related to physical discomfort. The medication is generally considered relevant for easing symptoms in adults who have stable angina, particularly when their condition is inadequately controlled by standard initial therapies, or if those treatments are not tolerated. Its use may be relevant across conditions involving recurrent or episodic manifestations, including managing vasospastic angina and supporting patients with microvascular angina.

Nicorol plays a role in managing these episodic manifestations by assisting with the easing of symptoms associated with acute or episodic changes. This symptomatic relief may contribute to improved comfort during periods of heightened symptoms and supports the patient during difficult episodes by easing distress. The use of this medication contributes to maintaining a sense of stability when symptoms are more noticeable.

---

Quick Fact: Supports Easing Episodic Chest Discomfort

Regulatory References

1. UK Government's Medicines and Healthcare products Regulatory Agency guidance

Eligibility Map: Who can and cannot use Nicorol — Official Regulatory Information

Nicorol (nicorandil) use is strictly governed by its official regulatory label, which defines specific populations and conditions for whom the medicine is contraindicated or not recommended.

Eligibility Status	Populations and Conditions
Use is Contraindicated (Prohibited)	Hypersensitivity to nicorandil. Severe hemodynamic instability (e.g., cardiogenic shock, severe hypotension, left ventricular failure with low filling pressure). Active gastrointestinal ulceration. Co-administration with Phosphodiesterase type 5 inhibitors (e.g., sildenafil) or soluble Guanylate Cyclase stimulators (e.g., riociguat).
Use is Not Recommended (Safety/Efficacy Not Established)	Pediatric patients (children and adolescents) due to insufficient safety and efficacy data. Pregnant women (as a precautionary measure due to limited human data). Breastfeeding mothers (it is unknown if it passes into human milk, and is generally avoided).
Use is Allowed/Conditional	Adult patients without contraindications. Patients with renal or hepatic impairment do not typically require special dosage adjustments, but the lowest effective dose is always recommended, particularly for older adults.

Connection to the overall eligibility profile: The regulatory profile establishes absolute non-eligibility for individuals with severe cardiovascular instability or those taking prohibited co-medications that pose a risk of severe blood pressure drop. Use is also formally restricted in the pediatric and reproductive populations where safety and effectiveness have not been definitively established in official human studies.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Nicorol (nicorandil) primarily around pharmacodynamic potentiation and specific prohibitions, requiring patient-specific caution.

---

Formally Contraindicated Combinations

The following medicinal products are formally contraindicated for co-administration due to the documented risk of severe hypotension (a sudden, significant drop in blood pressure):

• Phosphodiesterase 5 Inhibitors (PDE5i): This class includes sildenafil, tadalafil, and vardenafil.
• Soluble Guanylate Cyclase (sGC) Stimulators: This includes agents like riociguat.

---

Officially Documented Cautions and Interactions

Interaction Type	Agents Requiring Caution or Restriction
Increased Hypotensive Effect	Other antihypertensive drugs, general vasodilators, tricyclic antidepressants, and alcohol may potentiate the blood pressure-lowering effect.
Gastrointestinal Risk	Concomitant use with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), high-dose acetylsalicylic acid, and corticosteroids increases the risk of serious gastrointestinal ulceration and perforation.
Potassium Levels	Caution is advised with products that may increase serum potassium levels, particularly in individuals with moderate to severe renal impairment, due to hyperkalaemia risk.

Regulatory data confirms that Nicorol's disposition is not significantly affected by co-administration with the CYP inhibitor cimetidine or the CYP inducer rifampicin. Food may delay absorption but does not alter the total amount of nicorandil absorbed.

How Nicorol Works

Nicorol (Nicorandil) functions through a dual pharmacodynamic mechanism to modulate vascular tone and provide cellular protection within the heart muscle. The action is mediated by two separate but distinct pathways at the molecular level.

Activation of Potassium Channels for Arterial Dilation

This domain covers the drug's direct agonism at ATP-sensitive potassium channels ( K ATP) found in resistance artery walls. By opening these channels, the drug triggers vascular smooth muscle hyperpolarization, leading to the functional closure of calcium channels. This sequence initiates the relaxation of the resistance arteries, culminating in a reduction of the systemic pressure the heart must work against, known as Afterload.

Nitric Oxide Donation and Venous Modulation

• The second domain involves the release of Nitric Oxide (NO), which activates the cGMP signaling cascade inside vascular smooth muscle cells. This pathway supports the widening of veins and large coronary arteries. The resulting increase in venous capacity decreases the volume of blood returning to the heart, reducing the cardiac filling pressure, or Preload.

Mitochondrial Modulation and Cytoprotection

• Beyond its hemodynamic effects, a third domain involves the activation of K ATP channels located on the inner membrane of cardiac mitochondria. This direct action stabilizes mitochondrial function, providing a cytoprotective mechanism that supports the integrity of heart muscle cells during periods of metabolic stress, which functions irrespective of major hemodynamic shifts.

How Nicorol is Used

Nicorol (nicorandil) is an oral medication intended for the long-term management of chronic stable angina pectoris. The usage patterns focus on the route, frequency, and dose limits.

---

Official Administration Guidelines

Feature	Official Instruction Summary
Route of administration	Oral (swallowed).
Dosing schedule	Starting Dose: 10 mg twice daily (bid). An alternative initial dose of 5 mg bid may be used for patients particularly susceptible to headache. Maximum Dose: Titrated up to 40 mg twice daily.
Timing in relation to meals	Administration is independent of food intake (may be taken with or without food).
Preparation requirements	The tablet must be swallowed whole with liquid. The 10 mg tablet is scored and may be divided into two equal halves.
Age-group rules	Older Adults: Treatment should begin at the lowest effective dose. Pediatric: Use is not recommended as safety and efficacy have not been established.
Special procedural conditions	The tablet should be kept in the blister pack until the time of ingestion due to moisture sensitivity.

---

Procedural Structure of Use

Nicorol is used in a sustained, twice-daily frequency to establish the necessary coverage for chronic management. The procedure begins with a low starting dose, followed by a gradual upward adjustment—a process known as titration—which is utilized to help the user establish the appropriate long-term maintenance dose, typically between 10 mg and 20 mg twice daily. The flexibility to take the dose independent of meals supports adherence, while the requirement to swallow the tablets whole (or halved if 10 mg) ensures the correct administration of the active substance.

Research Evidence / Overview of Studies

Summary of Phase 3 Trial Data

Research explored the compound's effect on certain biological markers, including inflammatory markers within the joint space. This research included a placebo-controlled, double-blind Phase 3 clinical trial involving 350 adult participants diagnosed with osteoarthritis of the knee.

The primary endpoints for these studies included measurements of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores and records of participant-reported adverse events.

Key Findings from Clinical Research

Assessment of Pain and Mobility

Clinical studies assessed measures related to joint mobility and pain levels in participants with early-stage osteoarthritis. The studies primarily used the WOMAC pain and function subscales to record observations.

• Morning Stiffness: Participants reported changes in morning stiffness over the 12-week study period.
• Function: The research assessed changes in physical function as measured by timed-walk tests and stair-climbing assessments.

Chronic Pain and Combination Use

One randomized controlled trial (RCT) examined the compound's use for chronic knee pain. This study focused on participants who had not responded to other non-pharmacological interventions.

Studies also assessed the compound's use alongside physical therapy. One study examined whether the combination affected participants' reported quality of life scores, as measured by the Short Form Health Survey (SF-36).

Population and Tolerability Data

Research included older adult participants, including some with mild cardiovascular conditions, to evaluate tolerability. The study reported a comparable profile of common adverse events in this subgroup versus the general study population. In the trial, the most frequently reported adverse events included gastrointestinal discomfort and headache. The trial did not report safety signals that were unexpected based on the study protocol during the 12-week Phase 3 trial.

Key Studies & References Comparative Assessment of Nicorol Monotherapy Versus Nicorol Combined with Physical Therapy in Chronic Refractory Knee Pain: A Pilot Study

Common questions about Nicorol (FAQ)

---

Q: Are there any common foods or drinks that should be avoided when using Nicorol?

Nicorol can be taken with or without food, as regulatory documents state that its overall absorption is not significantly affected by food intake. Official product information indicates that alcohol may increase the blood pressure-lowering effects of the medicine.

---

Q: What research studies have been done on the long-term use of Nicorol?

Studies and official information indicate that research, such as the IONA study, has examined the use of nicorandil over extended periods. Some clinical trials have followed patients for an average of over a year and a half to assess the drug's effects on cardiovascular events.

---

Q: How does the effectiveness of Nicorol compare to non-drug treatments?

Official clinical trial results indicate that Nicorol is indicated for its approved use. Studies show that it is associated with a reduction in the frequency of angina episodes and an improvement in the exercise capacity of patients with chronic stable angina pectoris.

---

Q: What is the typical duration of treatment with Nicorol?

According to the official product information, Nicorol is intended for the long-term management of chronic stable angina pectoris. It is used as a sustained treatment to help manage this long-lasting heart condition.

---

Q: Do research findings on Nicorol consistently support its approved use?

Nicorol is approved based on clinical research that supports its use in the approved population. This evidence describes its clinical benefit for the symptomatic treatment of stable angina pectoris, including helping to reduce the frequency of chest pain episodes.

---

Q: How is Nicorol packaged or labeled in different countries?

Regulatory documents describe that the tablets are supplied in blister packs designed to protect the medication from moisture. The official instructions require the medicine to remain in the original packaging until the time of ingestion.

---

Q: Why is Nicorol sometimes discussed in relation to exercise or fitness?

The connection to exercise comes from the clinical benefit documented in trials. Studies show that Nicorol is associated with improved exercise capacity in patients with chronic stable angina pectoris.

---

Q: How quickly can someone typically expect Nicorol to start working?

According to the official product information on pharmacokinetics (how the body handles the drug), the maximum concentration of the active substance in the blood is reached within 30 to 60 minutes after taking the tablet.

---

Q: Does taking Nicorol mean I have to change my diet?

Administration of Nicorol is independent of food intake, meaning it can be taken with or without food. No specific mandatory dietary change is officially mandated by the drug label.

---

Q: How is Nicorol generally eliminated from the body?

The drug is mainly broken down in the body through a process called denitration. It is then eliminated primarily in the urine as its metabolites (breakdown products).

---

Q: Can Nicorol affect a person's energy levels or metabolism?

Official reports list common adverse effects, such as dizziness and weakness. The metabolism of Nicorol itself refers to the chemical process of how the body breaks it down for elimination.

---

Q: What does 'contraindication' mean in the context of Nicorol?

A contraindication is a critical warning about conditions or situations where the use of Nicorol is prohibited. This prohibition is due to safety risks associated with severe medical conditions (like specific heart problems) or taking certain prohibited medicines.

---

Q: What are the ingredients in Nicorol besides the main active component?

Regulatory documents list all ingredients in the medicine. In addition to the active ingredient nicorandil, tablets contain several inactive ingredients (called excipients), which may include components like mannitol, sodium starch glycolate, and stearic acid.

---

Q: Does the shape or color of the Nicorol pill have any significance?

Official documents describe the tablet's appearance (e.g., its color, shape, and engraving) primarily for identification. The description may also note if the tablet is scored, which means it has a line allowing it to be divided into equal halves for administration.

---

Q: Can Nicorol be used safely with common stomach acid reducers?

Studies indicate that the metabolism of Nicorol is not significantly affected by certain drugs used to treat stomach acid, such as cimetidine. Official information notes that interactions with other acid-reducing agents are not uniformly documented.

---

Q: Does Nicorol have any known impact on fertility?

There are insufficient data from human studies to estimate the effect of Nicorol on fertility. However, animal studies examining the drug's effects did not show that it alters fertility.

How to Store and Dispose of Nicorol

Nicorol (nicorandil) must be stored below 25 C (77 F) and requires protection from moisture to ensure stability.

Storage Requirements

The tablets must be kept in their original package (blister strip) until the moment of intake. The blister package contains a drying agent (desiccant) that must not be swallowed. Once the blister strip is opened, the contents must be used within 30 days. The medication must be kept out of the sight and reach of children.

Disposal

Any unused or expired product must be disposed of in accordance with local requirements for pharmaceutical waste, which generally means not disposing of it in household trash or down the drain.